A Pilot Study Evaluating the Feasibility of A Mobile Application to Collect Clinical, Magnetic Resonance Imaging Information and Genetic Data in Participants With Multiple Sclerosis
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Multiple Sclerosis
- Sponsor
- University of Southern California
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- Participants willing to provide genetic and MRI data via myMS
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
This is a pilot study looking at the feasibility of a mobile application (app) to collect data from active tasks (questionnaires, 6Mapp™, COGapp™, VISapp™), clinical magnetic resonance imaging information and conduct genome-wide association studies in subjects with multiple sclerosis. Participants will be self-referred to this study from different sources; patient advocacy groups, social media tools, clinicaltrials.gov, and flyers.
Detailed Description
This is a pilot study evaluating the feasibility of a mobile application "myMS™" to collect active clinical tasks (questionnaires, 6Mapp™, COGapp™, VISapp™), magnetic resonance imaging information and conduct genome-wide association studies in subjects with multiple sclerosis. Participants will be self-referred to this study from different sources; patient advocacy groups, social media tools, clinicaltrials.gov, and flyers. Specific aims of this pilot study are: 1. To determine the feasibility and work flow in prospectively collecting surveys, clinical tasks, magnetic resonance imaging (MRI) information for up to 200 self-referred adult MS participants, using mobile app myMS™. 2. To determine the feasibility of using interface between myMS™ and 23andMe® DNA Kits and 23andme password protected mobile app platform (GSR Dashboard) in collecting one biological (saliva) sample and distributing the genetic result (using commercially available results only, distributed by 23andme®), for up to 200 self-referred adult MS participants. This aim is for testing the system interface only. 23andme® has their own independent consent form and IRB coverage for their commercial product. 3. To estimate the percentage of registered participants that will meet eligibility criteria for MS. 4. To estimate the percentage of participants that a) complete all clinical tasks; b) complete all surveys; c) provide genetic information; and d) provide MRI scans.
Investigators
Daniel Pelletier
Professor of Neurology; Vice Chair, Clinical Research, Department of Neurology; Division Chief, Neuro-Immunology and USC Multiple Sclerosis Center
University of Southern California
Eligibility Criteria
Inclusion Criteria
- •Males or females participants with access to an iPhone 5 and above.
- •Participants willing to provide electronic consent.
- •Age 18 and above.
- •A diagnosis of MS (Polman, 2010), with dissemination in time and space. CIS participants will be included if they fulfil 3 of the 4 MRI criteria for dissemination in space as per Polman et al.
- •EDSS of between 0 and 8.0
Exclusion Criteria
- •Under 18 years of age
- •Participants who do not consent to participate.
- •Participants participating in ongoing MS clinical trials with non-approved drugs.
- •Any concurrent illness, disability or clinically significant abnormality (including laboratory tests) that may prevent the subject from safely completing the assessments required by the protocol.
Outcomes
Primary Outcomes
Participants willing to provide genetic and MRI data via myMS
Time Frame: 12 months
Proportion of participants with both genetic and MRI data available